Morphologic parameters relevant for visual outcome during anti-angiogenic therapy of neovascular age-related macular degeneration

Ophthalmology

Volumn 121, Issue 6, 2014, Pages 1237-1245

  Simader, Christian ^a   Ritter, Markus ^a   Bolz, Matthias ^a   Deák, Gabor G ^a   Mayr Sponer, Ulrike ^a   Golbaz, Isabelle ^a   Kundi, Michael ^b   Schmidt Erfurth, Ursula M ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b Medical University of Vienna   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENESIS INHIBITOR; RANIBIZUMAB;

ANTIANGIOGENIC THERAPY; ARTICLE; COMPUTER PROGRAM; CONTROLLED STUDY; CYST; DIABETIC RETINOPATHY; DOSAGE SCHEDULE COMPARISON; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG MEGADOSE; FOLLOW UP; HUMAN; LOADING DRUG DOSE; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MORPHOLOGY; MULTICENTER STUDY; OPTICAL COHERENCE TOMOGRAPHY DEVICE; PATHOPHYSIOLOGY; PHASE 3 CLINICAL TRIAL (TOPIC); PIGMENT EPITHELIUM; PRIORITY JOURNAL; PROGNOSIS; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; RETINA; RETINA MACULA AGE RELATED DEGENERATION; RETINAL THICKNESS; SUBRETINAL NEOVASCULARIZATION; TREATMENT DURATION; TREATMENT OUTCOME; VISUAL ACUITY;

AGED; AGED, 80 AND OVER; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL, HUMANIZED; DOUBLE-BLIND METHOD; FEMALE; HUMANS; INTRAVITREAL INJECTIONS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; QUALITY CONTROL; REPRODUCIBILITY OF RESULTS; RETINA; RETINAL DETACHMENT; RETREATMENT; SUBRETINAL FLUID; TOMOGRAPHY, OPTICAL COHERENCE; TREATMENT OUTCOME; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VISUAL ACUITY; WET MACULAR DEGENERATION;

EID: 84901790856     PISSN: 01616420     EISSN: 15494713     Source Type: Journal    
DOI: 10.1016/j.ophtha.2013.12.029     Document Type: Article

References (32)

1. N. Ferrara, R.D. Mass, C. Campa, and R. Kim Targeting VEGF-A to treat cancer and age-related macular degeneration Annu Rev Med 58 2007 491 504 (Pubitemid 46706529)
2. J.S. Penn, A. Madan, and R.B. Caldwell et al. Vascular endothelial growth factor in eye disease Prog Retin Eye Res 27 2008 331 371
3. S. Grisanti, and O. Tatar The role of vascular endothelial growth factor and other endogenous interplayers in age-related macular degeneration Prog Retin Eye Res 27 2008 372 390
4. N. Ferrara, L. Damico, and N. Shams et al. Development of ranibizumab, an anti-vascular endothelial growth factor antigen binding fragment, as therapy for neovascular age-related macular degeneration Retina 26 2006 859 870 (Pubitemid 44547437)
5. J. Lowe, J. Araujo, and J. Yang et al. Ranibizumab inhibits multiple forms of biologically active vascular endothelial growth factor in vitro and in vivo Exp Eye Res 85 2007 425 430 (Pubitemid 47542265)
6. P.J. Rosenfeld, D.M. Brown, J.S. Heier MARINA Study Group Ranibizumab for neovascular age-related macular degeneration N Engl J Med 355 2006 1419 1431 (Pubitemid 44511557)
7. D.M. Brown, P.K. Kaiser, M. Michels ANCHOR Study Group Ranibizumab versus verteporfin for neovascular age-related macular degeneration N Engl J Med 355 2006 1432 1444 (Pubitemid 44511558)
8. M.A. Singer, C.C. Awh, and S. Sadda et al. HORIZON: an open-label extension trial of ranibizumab for choroidal neovascularization secondary to age-related macular degeneration Ophthalmology 119 2012 1175 1183
9. C.D. Regillo, D.M. Brown, P. Abraham PIER Study Group Randomized, double-masked, sham-controlled trial of ranibizumab for neovascular age-related macular degeneration: PIER Study year 1 Am J Ophthalmol 145 2008 239 248
10. D.M. Brown, L. Tuomi, H. Shapiro PIER Study Group Anatomical measures as predictors of visual outcomes in ranibizumab-treated eyes with neovascular age-related macular degeneration Retina 33 2013 23 34
11. A.E. Fung, G.A. Lalwani, and P.J. Rosenfeld et al. An optical coherence tomography-guided, variable dosing regimen with intravitreal ranibizumab (Lucentis) for neovascular age-related macular degeneration Am J Ophthalmol 143 2007 566 583
12. G.A. Lalwani, P.J. Rosenfeld, and A.E. Fung et al. A variable-dosing regimen with intravitreal ranibizumab for neovascular age-related macular degeneration: year 2 of the PrONTO Study Am J Ophthalmol 148 2009 43 58
13. D.S. Boyer, J.S. Heier, and D.M. Brown et al. A Phase IIIb study to evaluate the safety of ranibizumab in subjects with neovascular age-related macular degeneration Ophthalmology 116 2009 1731 1739
14. F.G. Holz, W. Amoaku, J. Donate SUSTAIN Study Group Safety and efficacy of a flexible dosing regimen of ranibizumab in neovascular age-related macular degeneration: the SUSTAIN Study Ophthalmology 118 2011 663 671
15. Comparison of Age-related Macular Degeneration Treatments Trials (CATT) Research Group D.F. Martin, M.G. Maguire, and S.L. Fine et al. Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results Ophthalmology 119 2012 1388 1398
16. B.G. Busbee, A.C. Ho, D.M. Brown HARBOR Study Group Twelve-month efficacy and safety of 0.5 mg or 2.0 mg ranibizumab in patients with subfoveal neovascular age-related macular degeneration Ophthalmology 120 2013 1046 1056
17. U. Schmidt-Erfurth, B. Eldem, R. Guymer EXCITE Study Group Efficacy and safety of monthly versus quarterly ranibizumab treatment in neovascular age-related macular degeneration: the EXCITE Study Ophthalmology 118 2011 831 839
18. M. Bolz, C. Simader, and M. Ritter et al. Morphological and functional analysis of the loading regimen with intravitreal ranibizumab in neovascular age-related macular degeneration Br J Ophthalmol 94 2010 185 189
19. C.G. Kiss, W. Geitzenauer, and C. Simader et al. Evaluation of ranibizumab-induced changes in high-resolution optical coherence tomographic retinal morphology and their impact on visual function Invest Ophthalmol Vis Sci 50 2009 2376 2383
20. I. Golbaz, C. Ahlers, and G. Stock et al. Quantification of the therapeutic response of intraretinal, subretinal, and subpigment epithelial compartments in exudative AMD during anti-VEGF therapy Invest Ophthalmol Vis Sci 52 2011 1599 1605
21. P.A. Keane, F.M. Heussen, and Y. Ouyang et al. Assessment of differential pharmacodynamic effects using optical coherence tomography in neovascular age-related macular degeneration Invest Ophthalmol Vis Sci 53 2012 1152 1161
22. M. Ritter, J. Elledge, and C. Simader et al. Evaluation of optical coherence tomography findings in age-related macular degeneration: a reproducibility study of two independent reading centres Br J Ophthalmol 95 2011 381 385
23. J.S. Heier, A.N. Antoszyk, and P.R. Pavan et al. Ranibizumab for treatment of neovascular age-related macular degeneration: a phase I/II multicenter, controlled, multidose study Ophthalmology 113 2006 633 642
24. P.J. Rosenfeld, J.S. Heier, G. Hantsbarger, and N. Shams Tolerability and efficacy of multiple escalating doses of ranibizumab (Lucentis) for neovascular age-related macular degeneration Ophthalmology 113 2006 623 632
25. H. Dadgostar, A.A. Ventura, and J.Y. Chung et al. Evaluation of injection frequency and visual acuity outcomes for ranibizumab monotherapy in exudative age-related macular degeneration Ophthalmology 116 2009 1740 1747
26. F.C. DeCroos, C.A. Toth, S.S. Stinnett CATT Research Group Optical coherence tomography grading reproducibility during the Comparison of Age-Related Macular Degeneration Treatments Trials Ophthalmology 119 2012 2549 2557
27. G.S. Ying, J. Huang, M.G. Maguire Comparison of Age-Related Macular Degeneration Treatments Trials Research Group Baseline predictors for one-year visual outcomes with ranibizumab or bevacizumab for neovascular age-related macular degeneration Ophthalmology 120 2013 122 129
28. H. Hayashi, K. Yamashiro, and A. Tsujikawa et al. Association between foveal photoreceptor integrity and visual outcome in neovascular age-related macular degeneration Am J Ophthalmol 148 2009 83 89
29. L. Pelosini, C.C. Hull, and J.F. Boyce et al. Optical coherence tomography may be used to predict visual acuity in patients with macular edema Invest Ophthalmol Vis Sci 52 2011 2741 2748
30. P.J. Rosenfeld, H. Shapiro, L. Tuomi MARINA and ANCHOR Study Groups Characteristics of patients losing vision after 2 years of monthly dosing in the phase III ranibizumab clinical trials Ophthalmology 118 2011 523 530
31. W.A. Tseng, T. Thein, and K. Kinnunen et al. NLRP3 inflammasome activation in retinal pigment epithelial cells by lysosomal destabilization: implications for age-related macular degeneration Invest Ophthalmol Vis Sci 54 2013 110 120
32. C. Ahlers, E. Götzinger, and M. Pircher et al. Imaging of the retinal pigment epithelium in age-related macular degeneration using polarization-sensitive optical coherence tomography Invest Ophthalmol Vis Sci 51 2010 2149 2157